Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2007

View Archived Issues

New therapeutic agents for neurological disorders reported in recent patents

Novel therapeutic agents for cardiovascular disorders imparted in recent patents

New therapeutics for cancer covered in recent patent literature

Angptl4 validated as a drug target in cardiovascular disorders

PRT-054021 prevents venous thromboembolism after knee replacement

Tolevamer liquid fails to meet primary endpoint in CDAD trial

Roche and Alnylam form alliance in RNAi therapeutics

Bristol-Myers Squibb terminates MIV-170 license agreement with Medivir

Prolonged treatment with amylin mimetic peptide slows gastric emptying and improves glucose control

PTP1B inhibition improves insulin sensitivity via increases in adiponectin in obese monkeys

ProEthic files NDA for PRO-513 for migraine headaches

Silence Therapeutics and AstraZeneca to codevelop siRNA molecules

BHI-001: a novel Hsp90 inhibitor with improved therapeutic index

GW and Otsuka collaborate to research and develop cannabinoids

Clavis Pharma's phase II combination study of Elacyt approved

Positive results for transdermal delivery of hPTH (1-34) in phase I trials

Hsp32 validated as a therapeutic target in systemic mastocytosis

SPA agreement for pivotal study of oral Fodosine in cutaneous T-cell lymphoma

Japanese launch for Nesp

Positive preclinical results of new CRAC channel inhibitor in models of allergic inflammation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...